Adoption of Pharmacogenomic Testing: A Marketing Perspective
Pharmacogenomics is becoming an important part of clinical practice and it is considered one of the basic pillars of personalised medicine. However, the rate of pharmacogenomics adoption is still low in many healthcare systems, especially in low- or middle-income countries. The low level of awarenes...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.724311/full |
| _version_ | 1819136284035121152 |
|---|---|
| author | Margarita-Ioanna Koufaki Kariofyllis Karamperis Kariofyllis Karamperis Polixeni Vitsa Konstantinos Vasileiou George P. Patrinos George P. Patrinos George P. Patrinos Christina Mitropoulou |
| author_facet | Margarita-Ioanna Koufaki Kariofyllis Karamperis Kariofyllis Karamperis Polixeni Vitsa Konstantinos Vasileiou George P. Patrinos George P. Patrinos George P. Patrinos Christina Mitropoulou |
| author_sort | Margarita-Ioanna Koufaki |
| collection | DOAJ |
| description | Pharmacogenomics is becoming an important part of clinical practice and it is considered one of the basic pillars of personalised medicine. However, the rate of pharmacogenomics adoption is still low in many healthcare systems, especially in low- or middle-income countries. The low level of awareness of healthcare specialists could be a potential reason due to which pharmacogenomics application is still in a premature stage but there are several other barriers that impede the aforementioned process, including the lack of the proper promotion of pharmacogenomic testing among interested stakeholders, such as healthcare professionals and biomedical scientists. In this study, we outline the available marketing theories and innovation that are applied to personalized medicine interventions that would catalyze the adoption of pharmacogenomic testing services in clinical practice. We also present the current ethical and legal framework about genomic data and propose ways to tackle the main concerns mentioned in the literature and to improve the marketing perspective of PGx. |
| first_indexed | 2024-12-22T10:32:32Z |
| format | Article |
| id | doaj.art-82945050842547b19589c3161f19b463 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-22T10:32:32Z |
| publishDate | 2021-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-82945050842547b19589c3161f19b4632022-12-21T18:29:16ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-09-011210.3389/fphar.2021.724311724311Adoption of Pharmacogenomic Testing: A Marketing PerspectiveMargarita-Ioanna Koufaki0Kariofyllis Karamperis1Kariofyllis Karamperis2Polixeni Vitsa3Konstantinos Vasileiou4George P. Patrinos5George P. Patrinos6George P. Patrinos7Christina Mitropoulou8University of Patras School of Health Sciences, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, Patras, GreeceUniversity of Patras School of Health Sciences, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, Patras, GreeceThe Golden Helix Foundation, London, United KingdomUniversity of Patras School of Health Sciences, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, Patras, GreeceUniversity of Patras School of Health Sciences, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, Patras, GreeceUniversity of Patras School of Health Sciences, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy, Patras, GreeceUnited Arab Emirates University, College of Medicine and Health Sciences, Department of Pathology, Al-Ain, United Arab EmiratesUnited Arab Emirates University, Zayed Center for Health Sciences, Al-Ain, United Arab EmiratesThe Golden Helix Foundation, London, United KingdomPharmacogenomics is becoming an important part of clinical practice and it is considered one of the basic pillars of personalised medicine. However, the rate of pharmacogenomics adoption is still low in many healthcare systems, especially in low- or middle-income countries. The low level of awareness of healthcare specialists could be a potential reason due to which pharmacogenomics application is still in a premature stage but there are several other barriers that impede the aforementioned process, including the lack of the proper promotion of pharmacogenomic testing among interested stakeholders, such as healthcare professionals and biomedical scientists. In this study, we outline the available marketing theories and innovation that are applied to personalized medicine interventions that would catalyze the adoption of pharmacogenomic testing services in clinical practice. We also present the current ethical and legal framework about genomic data and propose ways to tackle the main concerns mentioned in the literature and to improve the marketing perspective of PGx.https://www.frontiersin.org/articles/10.3389/fphar.2021.724311/fullpersonalized medicinepharmacogenomicsmarketing strategiesinnovationawarenessgenetic testing services |
| spellingShingle | Margarita-Ioanna Koufaki Kariofyllis Karamperis Kariofyllis Karamperis Polixeni Vitsa Konstantinos Vasileiou George P. Patrinos George P. Patrinos George P. Patrinos Christina Mitropoulou Adoption of Pharmacogenomic Testing: A Marketing Perspective Frontiers in Pharmacology personalized medicine pharmacogenomics marketing strategies innovation awareness genetic testing services |
| title | Adoption of Pharmacogenomic Testing: A Marketing Perspective |
| title_full | Adoption of Pharmacogenomic Testing: A Marketing Perspective |
| title_fullStr | Adoption of Pharmacogenomic Testing: A Marketing Perspective |
| title_full_unstemmed | Adoption of Pharmacogenomic Testing: A Marketing Perspective |
| title_short | Adoption of Pharmacogenomic Testing: A Marketing Perspective |
| title_sort | adoption of pharmacogenomic testing a marketing perspective |
| topic | personalized medicine pharmacogenomics marketing strategies innovation awareness genetic testing services |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.724311/full |
| work_keys_str_mv | AT margaritaioannakoufaki adoptionofpharmacogenomictestingamarketingperspective AT kariofylliskaramperis adoptionofpharmacogenomictestingamarketingperspective AT kariofylliskaramperis adoptionofpharmacogenomictestingamarketingperspective AT polixenivitsa adoptionofpharmacogenomictestingamarketingperspective AT konstantinosvasileiou adoptionofpharmacogenomictestingamarketingperspective AT georgeppatrinos adoptionofpharmacogenomictestingamarketingperspective AT georgeppatrinos adoptionofpharmacogenomictestingamarketingperspective AT georgeppatrinos adoptionofpharmacogenomictestingamarketingperspective AT christinamitropoulou adoptionofpharmacogenomictestingamarketingperspective |